健脾疏肝汤加减联合恩替卡韦治疗乙肝肝硬化失代偿期的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of modified Jianpi Shugan Decoction combined with Entecavir in treatment of decompensated cirrhosis.Methods A total of 160 patients with decompensated cirrhosis who were admitted to the First People′s Hospital of Jiujiang City in Jiangxi Province from May 2017 to June 2019 were selected as the research subjects.All the patients were divided into control group (80 cases) and observation group (80 cases) according to the random number table method.The control group was treated with Entecavir,while observation group was treated with modified Jianpi Shugan Decoction combined with Entecavir.The total effective rate,traditional Chinese medicine(TCM) syndrome score,liver function indexes (aspartate aminotransferase [AST],alanine transaminase [ALT],total bilirubin [TBil],albumin [ALB]) before and after treatment,and the incidence of adverse reactions were compared between the two groups..Results The total effective rate of the observation group was higher than that of the control group,with statistical difference (P<0.05).The TCM syndrome score of the observation group was lower than that of the control group after treatment,with statistical difference (P<0.05).The levels of AST,ALT,TBil,ALB and HBV-DNA in the observation group were lower than those in the control group after treatment,with statistical differences (P<0.05).No obvious adverse reactions occurred during the two groups of medication.Conclusion Modified Jianpi Shugan Decoction combined with Entecavir in treatment of patients with decompensated cirrhosis is effective,it can decrease TCM syndrome score,improve indexes of liver function,and have no obvious adverse reactions,which has high safety and is worthy of promotion and application.

Key words： Decompensated cirrhosis Jianpi Shugan Decoction Entecavir Traditional Chinese medicine syndrome score Liver function Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Yu
	KE Hua-jing
	WU Gang

Cite this article:

ZHANG Yu,KE Hua-jing,WU Gang. Effect of modified Jianpi Shugan Decoction combined with Entecavir in treatment of decompensated cirrhosis[J]. 中国当代医药, 2020, 27(36): 67-69转73.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I36/67

[1]	应灵军，陈华忠，张建伟，等.代偿期乙型肝炎肝硬化患者长期抗病毒治疗后临床特点和肝脏组织学改变[J].中华临床感染病杂志，2016，9（1）：13-18.
[2]	李连海，齐敏.不同核苷类似物治疗乙型肝炎肝硬化失代偿期的疗效及对相关炎性细胞因子水平的影响[J].广西医科大学学报，2016，33（5）：849-851.
[3]	中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年版）[J].中国病毒病杂志，2015，11（5）：401-424.
[4]	国家中医药管理局.中医临床病症诊断疗效标准[M].北京：中国中医药出版社，2017：16.
[5]	杨红丽.健康体检人群中乙型肝炎病毒感染状况调查[J].中国药物与临床，2016，16（7）：978-979.
[6]	于乐成，侯金林.乙型肝炎病毒感染抗病毒治疗临床转归评估指标现状及展望[J].中华肝脏病杂志，2017，25（7）：500-505.
[7]	段景山，张俊兄.长期抗病毒治疗对代偿期乙型肝炎肝硬化患者一般检验指标及肝灌注参数的影响[J].医学临床研究，2016，33（12）：2315-2319.
[8]	侯丽娟，李玉华，王宏伟，等.恩替卡韦治疗慢性乙型肝炎的疗效[J].中华医院感染学杂志，2019，29（21）：3242-3245，3255.
[9]	刘雷，张艳.恩替卡韦联合化瘀软肝汤治疗乙型肝炎肝硬化代偿期患者51例[J].中西医结合肝病杂志，2019，29（3）：259-260.
[10]	翟金海，符玉章，花海兵.中医辨治酒精性肝硬化失代偿期案[J].中国中医药信息杂志，2019，26（6）：114-115.
[11]	刘会坡，邓素美，李俊颖，等.温阳益气汤联合恩替卡韦治疗老年失代偿期乙肝后肝硬化患者临床疗效研究[J].河北医学，2016，22（4）：649-651.
[12]	康燕能，王敏，林辉瑶，等.慢性乙型肝炎中医证型与客观指标相关性研究概况[J].陕西中医，2018，39（7）：983-985.
[13]	徐祥涛，刘丽娜，乔飞，等.疏肝健脾汤联合西药对慢性乙肝患者肝纤维化及细胞免疫功能的影响[J].中药材，2018，41（9）：2227-2229.
[14]	连媛媛.疏肝健脾活血方对乙肝肝硬化的疗效和患者肝功能及凝血功能的影响[J].中国煤炭工业医学杂志，2019，22（2）：195-197.
[15]	王志勇，许俊.舒肝健脾汤对乙型肝炎肝硬化肠道菌群移位及腹水的影响[J].陕西中医，2017，38（10）：1405-1406.